Watch out Bayer, Roche is coming for you with a discount price rival to the tumor agnostic drug you got from Loxo
Just ahead of schedule the FDA has come through with a key approval for Genentech’s tumor agnostic entrectinib — now headed to the market as Rozlytrek.
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
